Skip to main content

Table 3 Incremental cost-effectiveness of artemether-lumefantrine including second line treatment

From: A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia

 

AL

SP

1. Total patients

55,509

55,509

2. First wave first-line, US$a

407,436.06

343,600.71

3. Second wave first-line, US$b

58,263.36

143,968.70

4. Second line treatment, US$c

6,088.60

182,575.57

5. Incremental cost, US$

-176,486.97

-

6. ACER including second line treatment, US$

9.92

20.78

7. ICER including second line treatment, US$

-11.52

-

  1. (a) All patients receive first wave first-line
  2. (b) 14.7% of AL and 41.9% of SP recipients fail first-line and receive repeated dosage
  3. (c) cost of second line treatment is us$16.32
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us